Tarsus Pharmaceuticals, Inc.TARSEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9.90% | 3.8M | flat | 2024-11-08 |
| RTW Investments, LP | 9.50% | 3.2M | — | 2024-02-14 |
| NOS. of Above Persons | 6.70% | 2.2M | ▲ +1.87pp | 2024-02-14 |
| Paradigm BioCapital Advisors LP | 6.40% | 2.4M | ▲ +0.60pp | 2024-11-14 |
| Cowen Financial Products LLC | 5.77% | 1.9M | ▲ +0.55pp | 2024-02-02 |
| Jennison Associates LLC | 5.70% | 2.2M | — | 2024-11-12 |
| The Vanguard Group | 5.51% | 2.1M | flat | 2024-11-12 |
| Frazier Life Sciences IX, L.P . | 4.20% | 1.6M | — | 2024-11-06 |
| Vivo | 2.70% | 894.8K | — | 2024-02-13 |
| Cormorant Asset Management, LP | 1.31% | 500.0K | — | 2024-11-14 |
| Prudential Financial, Inc. | — | 2.3M | — | 2024-11-14 |
Insider Transactions
Net 90d: −$7.94M · buys $0 / sells $7.94MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-20 | Seshadri Neervannan | Chief Operating Officer | Sell (open market) | 3.0K | $66.75 | $199.5K |
| 2026-03-19 | Bryan Wahl | General Counsel | Sell (open market) | 4.2K | $67.00 | $283.5K |
| 2026-03-19 | Whitfield Dianne C. | Chief Human Resources Officer | Sell (open market) | 4.2K | $67.00 | $279.7K |
| 2026-03-19 | Seshadri Neervannan | Chief Operating Officer | Sell (open market) | 4.6K | $67.00 | $307.5K |
| 2026-03-19 | Farrow Jeffrey S | See Remarks | Sell (open market) | 2.2K | $67.00 | $146.5K |
| 2026-03-19 | Azamian Bobak R. | President/CEO and Board Chair | Sell (open market) | 12.0K | $67.00 | $801.6K |
| 2026-03-19 | Aziz Mottiwala | Chief Commercial Officer | Sell (open market) | 4.4K | $67.00 | $297.5K |
| 2026-03-19 | Lin Elizabeth Yeu | Chief Medical Officer | Sell (open market) | 390 | $67.00 | $26.1K |
| 2026-03-18 | Bryan Wahl | General Counsel | Sell (open market) | 4.1K | $68.71 | $283.4K |
| 2026-03-18 | Whitfield Dianne C. | Chief Human Resources Officer | Sell (open market) | 4.1K | $68.71 | $279.7K |
1–10 of 33
Page 1 / 4